Jennifer L. Mcneer

Dr. Jennifer L. Mcneer

Pediatrics
100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Referral required
Before you request
100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 

Overview

Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children's Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children's Hospital.After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children's Memorial Hospital (now Lurie Children's Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children's Memorial Hospital, and during her fellowship earned a master's degree in clinical investigation at Northwestern University Feinberg School of Medicine.Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children's Oncology Group.Dr. McNeer's clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children's Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.

Her clinical expertise encompasses Childhood Pancreatitis, Febrile Neutropenia, Infantile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration.

Dr. Mcneer is board certified in American Board Of Pediatrics, American Board Of Pediatrics , and American Board Of Pediatrics. She is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 21 clinical trials. Dr. Mcneer is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in IL

Board Certifications

American Board Of Pediatrics
American Board Of Pediatrics
American Board Of Pediatrics

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

Primary Children's Hospital - Hematology Oncology
100 North Mario Capecchi Drive, Suite 1400, Salt Lake City, UT 84113
Other Locations
Pediatric Hematology-oncology - Hci
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Pediatric Hematology-oncology - University Of Utah Hospital
50 N Medical Dr, Salt Lake City, UT 84132

Additional Areas of Focus

Dr. Mcneer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Genetic
Study Phase: Not Applicable
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
View 8 Less Clinical Trials

42 Total Publications

Updates in Childhood Acute Lymphoblastic Leukemia.
Updates in Childhood Acute Lymphoblastic Leukemia.
Journal: Hematology/oncology clinics of North America
Published: June 10, 2026
Similar Doctors
Expertise in
1
conditions
Dr. Anne M. Moon
Pediatrics
Expertise in
1
conditions
Dr. Anne M. Moon
Pediatrics
Referral may be required
Before you request

Primary Children's Hospital

100 N Mario Capecchi Dr # 2, 
Salt Lake City, UT 
 (0.5 miles away)
801-581-2121
Languages Spoken:
English
Accepting New Patients

Anne Moon is a Pediatrics provider practicing medicine in Salt Lake City, Utah. Dr. Moon is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ulnar-Mammary Syndrome and Cerebral Hypoxia. Dr. Moon is currently accepting new patients.

Expertise in
4
conditions
Expertise in
4
conditions
Referral may be required
Before you request

Pediatric Emergency Medicine

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-662-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shana Godfred-Cato is a Pediatrics provider practicing medicine in Salt Lake City, Utah. Dr. Godfred-Cato is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Pediatric Myocarditis, Microcephaly, and Achalasia Microcephaly Syndrome. Dr. Godfred-Cato is board certified in American Osteopathic Board Of Pediatrics and American Board Of Pediatrics. Dr. Godfred-Cato is currently accepting new patients.

Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required
Before you request

Pediatric Gastroenterology

81 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-213-3599
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Guthery is the Chief of the Division of Pediatric Gastroenterology, Hepatology, Nutrition at Primary Children's Hospital. His interests include the care of infants, children and adolescents with Crohn's disease, ulcerative colitis and liver disease. His research involves understanding the genetic basis of and improving treatments for these conditions. Dr. Guthery is board certified in General Pediatrics, Pediatric Gastroenterology, and Pediatric Transplant Hepatology. Dr. Guthery has served as an expert clinical/scientific consultant for several non-profit agencies and the National Institutes of Health. He is listed among the Best Doctors in America. Dr. Guthery is a native of the Mountain West and has been at the University of Utah and Primary Children's Hospital for 18 years. Dr. Guthery is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Biliary Atresia, Viral Gastroenteritis, Esophagitis, Alpha-1 Antitrypsin Deficiency (AATD), and Gastrostomy. Dr. Guthery is board certified in American Board Of Pediatrics, American Board Of Pediatrics , American Board Of Pediatrics , and American Board Of Pediatrics. Dr. Guthery is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer L. Mcneer

How do I make an appointment with Dr. Jennifer L. Mcneer?

You can book an appointment with Dr. Jennifer L. Mcneer by calling their office at 801-662-4700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer L. Mcneer a top-rated expert for Childhood Pancreatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer L. Mcneer is classified as an Experienced expert for Childhood Pancreatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer L. Mcneer specialize in?

While Dr. Jennifer L. Mcneer is a Pediatrics, they have specific expertise in Childhood Pancreatitis, Febrile Neutropenia, and Infantile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Jennifer L. Mcneer participate in research or clinical trials?

Yes. Dr. Jennifer L. Mcneer has published 42 articles and abstracts on conditions like Childhood Pancreatitis. You can view a list of Dr. Jennifer L. Mcneer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer L. Mcneer accept my insurance?

Dr. Jennifer L. Mcneer accepts most major insurance plans, including Aetna and BridgeSpan. We recommend calling the office directly at 801-662-4700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcneer's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile